Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00463385 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study of Pomalidomide in Myelofibrosis With Myeloid Metaplasia
A Phase 2 study, sponsored by Celgene.
- Completed
- Registry status
- Phase 2
- Development phase
- 88
- Enrollment target
NCT00463385 is a Phase 2 study that has completed, run by Celgene. The registered enrollment target is 88 participants.
The verdict
NCT00463385, a Phase 2 study, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 88 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety of and to select a treatment regimen of pomalidomide (CC-4047) either as single-agent or in combination with prednisone to study further in patients with myelofibrosis with myeloid metaplasia (MMM).
Interventions
- DRUG Prednisone
- DRUG Pomalidomide
- DRUG Placebo to pomalidomide
- DRUG Placebo to prednisone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2007-04-01 |
| Est. Completion | 2013-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00463385
The ClinicalTrials.gov registry entry for NCT00463385 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Prednisone is the first listed.
NCT00463385 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00463385 about?
NCT00463385 is a clinical study titled "A Phase II Study of Pomalidomide in Myelofibrosis With Myeloid Metaplasia". The purpose of this study is to determine the safety of and to select a treatment regimen of pomalidomide (CC-4047) either as single-agent or in combination with prednisone to study further in patients with myelofibrosis with myeloid metaplasia (MMM).
What is the current status of trial NCT00463385?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 88 participants. The study started on 2007-04-01. Estimated completion is 2013-12-31.
What interventions are being tested in trial NCT00463385?
The interventions under investigation include: Prednisone (DRUG), Pomalidomide (DRUG), Placebo to pomalidomide (DRUG), Placebo to prednisone (DRUG).
Who is sponsoring clinical trial NCT00463385?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.